New tool for pre-surgical detection of kidney cancers may help patients avoid unnecessary surgeries
May 31, 2010 by admin · Leave a Comment
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
SAN FRANCISCO, CA. (June 1, 2010)Kidney cancer is a radiographic diagnosis which means treatment decisions are often made based on the findings of a solid mass on CT or MRI. Unfortunately these tests cannot distinguish the different types of kidney cancers which have variable risks. As more Americans continue to be scanned as part of their evaluation for various ailments and symptoms, the number of kidney tumors found serendipitously has increased such that now up to 70 percent of kidney cancers are discovered incidentally.
Mayo Clinic researchers find gene they believe is key to kidney cancer
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic
JACKSONVILLE, Fla. Researchers at Mayo Clinic’s campus in Florida have discovered a key gene that, when turned off, promotes the development of common kidney cancer. Their findings suggest that a combination of agents now being tested in other cancers may turn the gene back on, providing a much-needed therapy for the difficult-to-treat cancer.
Mayo Clinic researchers find genetic secrets to common kidney cancer
May 17, 2010 by admin · Leave a Comment
Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic
JACKSONVILLE, Fla. By examining expression of every human gene in clear cell renal cell carcinoma (ccRCC) compared to normal kidney cells, researchers at Mayo Clinic’s campus in Florida have discovered gene signatures they say explain much of the biology of this common and difficult-to-treat kidney cancer.
Milk and risk of renal cell cancer: Genetic research sheds new light
Contact: Tara Yates
tara.yates@aacr.org
267-646-0558
American Association for Cancer Research
PHILADELPHIA While previous research had suggested that drinking milk was related to factors that may increase the risk of renal cell cancer, results of a recent study exploiting the genetic contribution to variation in milk consumption suggest that this may not be the case.
Urine test for kidney cancer a step closer to development
April 6, 2010 by admin · Leave a Comment
Contact: Jim Dryden
jdryden@wustl.edu
314-286-0110
Washington University School of Medicine
Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.
Drug for advanced kidney cancer shrinks tumors prior to surgery
February 16, 2010 by admin · Leave a Comment
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Chapel Hill, N.C. - More than 57,000 Americans face a diagnosis of kidney cancer each year. Now patients with advanced disease may soon have another treatment option. Physicians who conducted a pilot study at UNC Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug sorafenib can reduce the size of large tumors and could be safely undertaken administered without adding significantly to the risks of surgery.
Promising results shown for kidney cancer drug
February 3, 2010 by admin · Leave a Comment
Contact: Ilene Rush
irush@shro.org
215-635-5162
Sbarro Health Research Organization
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.
FDA approves new drug for advanced kidney cancer
March 31, 2009 by admin · Leave a Comment
The U.S. Food and Drug Administration approved for sale a kidney-cancer drug that Novartis AG hopes to eventually expand to a variety of other cancers.
Discovery offers hope for treating kidney cancer
December 23, 2008 by admin · Leave a Comment
Kidney cancer is typically without symptoms until it has spread to other organs, when it is also the most difficult to treat. Newer chemotherapies show great promise for extending survival during later disease stages, but they can also be highly toxic.
Drug fends off kidney cancer progression
May 16, 2008 by admin · Leave a Comment
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus (RAD001) significantly delays cancer progression in patients with metastatic kidney cancer whose disease had worsened on other treatments. The study was led by Robert Motzer, MD, an attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), who will present the findings on May 31 at the annual meeting of the American Society for Clinical Oncology.
